Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 18.8
(2.73%)
SEK 18.8
(2.73%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 85.22 Million SEK | -57.93% |
| 2022 | 202.6 Million SEK | 6.39% |
| 2021 | 190.43 Million SEK | 108.76% |
| 2020 | 91.22 Million SEK | 43.17% |
| 2019 | 63.71 Million SEK | 133.59% |
| 2018 | 27.27 Million SEK | -37.51% |
| 2017 | 43.64 Million SEK | 2.77% |
| 2016 | 42.46 Million SEK | -17.84% |
| 2015 | 51.69 Million SEK | -10.83% |
| 2014 | 57.96 Million SEK | 22.89% |
| 2013 | 47.17 Million SEK | -1.37% |
| 2012 | 47.82 Million SEK | 514.91% |
| 2011 | 7.77 Million SEK | 96.59% |
| 2010 | 3.95 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 93.03 Million SEK | 39.65% |
| 2024 Q1 | 66.62 Million SEK | -21.83% |
| 2023 Q1 | 167.49 Million SEK | -17.33% |
| 2023 Q4 | 85.22 Million SEK | -18.66% |
| 2023 FY | 85.22 Million SEK | -57.93% |
| 2023 Q3 | 104.78 Million SEK | -19.54% |
| 2023 Q2 | 130.22 Million SEK | -22.25% |
| 2022 Q3 | 123.27 Million SEK | -19.35% |
| 2022 FY | 202.6 Million SEK | 6.39% |
| 2022 Q2 | 152.85 Million SEK | -11.5% |
| 2022 Q4 | 202.6 Million SEK | 64.35% |
| 2022 Q1 | 172.72 Million SEK | -9.3% |
| 2021 FY | 190.43 Million SEK | 108.76% |
| 2021 Q1 | 81.62 Million SEK | -10.52% |
| 2021 Q4 | 190.43 Million SEK | 414.19% |
| 2021 Q3 | 37.03 Million SEK | -45.2% |
| 2021 Q2 | 67.58 Million SEK | -17.21% |
| 2020 Q4 | 91.22 Million SEK | 217.07% |
| 2020 FY | 91.22 Million SEK | 43.17% |
| 2020 Q2 | 47.13 Million SEK | -18.12% |
| 2020 Q3 | 28.77 Million SEK | -38.96% |
| 2020 Q1 | 57.56 Million SEK | -9.65% |
| 2019 Q1 | 53.24 Million SEK | 95.21% |
| 2019 Q4 | 63.71 Million SEK | 24.04% |
| 2019 Q3 | 51.36 Million SEK | -21.14% |
| 2019 FY | 63.71 Million SEK | 133.59% |
| 2019 Q2 | 65.13 Million SEK | 22.32% |
| 2018 Q1 | 44.1 Million SEK | 1.06% |
| 2018 FY | 27.27 Million SEK | -37.51% |
| 2018 Q4 | 27.27 Million SEK | -43.52% |
| 2018 Q3 | 48.29 Million SEK | -24.4% |
| 2018 Q2 | 63.87 Million SEK | 44.82% |
| 2017 Q2 | 68.42 Million SEK | 76.17% |
| 2017 Q4 | 43.64 Million SEK | -17.14% |
| 2017 FY | 43.64 Million SEK | 2.77% |
| 2017 Q3 | 52.67 Million SEK | -23.02% |
| 2017 Q1 | 38.84 Million SEK | -8.54% |
| 2016 Q3 | 60.34 Million SEK | -16.77% |
| 2016 Q2 | 72.5 Million SEK | 70.26% |
| 2016 Q1 | 42.58 Million SEK | -17.62% |
| 2016 FY | 42.46 Million SEK | -17.84% |
| 2016 Q4 | 42.46 Million SEK | -29.62% |
| 2015 FY | 51.69 Million SEK | -10.83% |
| 2015 Q2 | 52.46 Million SEK | -11.56% |
| 2015 Q4 | 51.69 Million SEK | 22.1% |
| 2015 Q3 | 42.33 Million SEK | -19.31% |
| 2015 Q1 | 59.32 Million SEK | 2.34% |
| 2014 Q1 | 47.58 Million SEK | 0.88% |
| 2014 Q4 | 57.96 Million SEK | -3.56% |
| 2014 FY | 57.96 Million SEK | 22.89% |
| 2014 Q3 | 60.1 Million SEK | -1.8% |
| 2014 Q2 | 61.2 Million SEK | 28.62% |
| 2013 Q2 | 45.58 Million SEK | 96994.47% |
| 2013 Q1 | 46.94 Thousand SEK | -99.9% |
| 2013 Q3 | 43.58 Million SEK | -4.39% |
| 2013 Q4 | 47.17 Million SEK | 8.23% |
| 2013 FY | 47.17 Million SEK | -1.37% |
| 2012 FY | 47.82 Million SEK | 514.91% |
| 2012 Q4 | 47.82 Million SEK | 0.0% |
| 2011 FY | 7.77 Million SEK | 96.59% |
| 2010 FY | 3.95 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 28.048% |
| Ziccum AB (publ) | 14.97 Million SEK | -469.243% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -325.263% |
| BioArctic AB (publ) | 1.18 Billion SEK | 92.814% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -36.632% |
| Mendus AB (publ) | 755.95 Million SEK | 88.726% |
| Genovis AB (publ.) | 288.85 Million SEK | 70.495% |
| Intervacc AB (publ) | 259.61 Million SEK | 67.171% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -103.12% |
| Active Biotech AB (publ) | 44 Million SEK | -93.698% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 69.425% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -37.127% |
| Aptahem AB (publ) | 63.02 Million SEK | -35.227% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 82.826% |
| Kancera AB (publ) | 65.64 Million SEK | -29.834% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 75.742% |
| Fluicell AB (publ) | 9.34 Million SEK | -812.495% |
| Saniona AB (publ) | 64.14 Million SEK | -32.87% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -153.637% |
| Biovica International AB (publ) | 131.4 Million SEK | 35.143% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -60.851% |
| AcouSort AB (publ) | 34.51 Million SEK | -146.942% |
| Xintela AB (publ) | 18.39 Million SEK | -363.316% |
| Abliva AB (publ) | 87.49 Million SEK | 2.597% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 88.789% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.227% |
| OncoZenge AB (publ) | 20.34 Million SEK | -319.012% |
| Amniotics AB (publ) | 26.08 Million SEK | -226.715% |
| 2cureX AB (publ) | 16.62 Million SEK | -412.644% |
| CombiGene AB (publ) | 120.61 Million SEK | 29.338% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1302.452% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.516% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.533% |
| Corline Biomedical AB | 100.1 Million SEK | 14.862% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 51.882% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 39.382% |
| I-Tech AB | 152.44 Million SEK | 44.093% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 91.628% |
| Cyxone AB (publ) | 43.65 Million SEK | -95.228% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -8.305% |
| Biosergen AB | 7.2 Million SEK | -1083.544% |
| Cantargia AB (publ) | 223.71 Million SEK | 61.903% |
| NextCell Pharma AB | 81.28 Million SEK | -4.846% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 88.863% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -182.461% |
| Nanologica AB (publ) | 77.42 Million SEK | -10.071% |
| SynAct Pharma AB | 228.01 Million SEK | 62.623% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -218.451% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -292.699% |
| LIDDS AB (publ) | 17.65 Million SEK | -382.736% |
| Lipum AB (publ) | 12.11 Million SEK | -603.774% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 93.913% |
| Alzinova AB (publ) | 123.18 Million SEK | 30.816% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 64.247% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -908.007% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -473.186% |
| Simris Alg AB (publ) | 174.55 Million SEK | 51.174% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 60.732% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 86.959% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 2.119% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -198.958% |